Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis	apoptosis	Drug	Cisplatin
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	laryngeal cancer
ICD-0-3	C32
Methods	qPCR, Western blot, Luciferase reporter assay
Sample	laryngeal cancer tissues, cell lines (HEp-2/R)
Expression Pattern	up-regulated
Function Description	AFAP1-AS1 was up-regulated in laryngeal carcinoma specimens and cells, but also that stemness-associated genes were overexpressed. Silencing of AFAP1-AS1 promoted HEp-2 cell chemoresistance under cisplatin treatment. Expression of AFAP1-AS1 was increased in drug-resistant Hep-2 cells. Apoptosis assays of AFAP1-AS1-silenced HEp-2 cells treated with 8 ?mol L?? cisplatin showed that silencing AFAP1-AS1 significantly elevated cell apoptosis. Luciferase reporter and qRT-PCR assays of AFAP1-AS1 and miR-320a levels in human specimens and cell cultures indicated that AFAP1-AS1 negatively regulates miR-320a. After cloning the 3'-untranslated regions (3'-UTR) of RBPJ into a luciferase reporter, we determined that miR-320a did in fact reduce RBPJ mRNA and protein levels. Ultimately, we determined that AFAP1-AS1 increases RBPJ expression by negatively regulating miR-320a and RBPJ overexpression rescues stemness and chemoresistance inhibited by AFAP1-AS1 silencing.
Pubmed ID	29971915
Year	2018
Title	Long Non-Coding RNA AFAP1-AS1/miR-320a/RBPJ Axis Regulates Laryngeal Carcinoma Cell Stemness and Chemoresistance

External Links